Showing results (431-440 of 586) with videos related to

Sort By:
Pageof 59
Journal for Immunotherapy of Cancer|November 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variantsGiulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury, et al.
Journal of the American Chemical Society|July 5, 2019
Understanding Gas Storage in Cuboctahedral Porous Coordination CagesGregory R Lorzing, Aeri J Gosselin, Benjamin A Trump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Scientific Reports|December 17, 2020
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancerReham Abdel-Wahab, Timothy A Yap, Russell Madison, et al.
Angewandte Chemie (International Ed. in English)|June 15, 2021
Synergistic Catalysis by Brønsted Acid/Carbodicarbene Mimicking Frustrated Lewis Pair-Like ReactivityYi-Chen Chan, Yuna Bai, Wen-Ching Chen, et al.
Inorganic Chemistry|October 1, 2021
Synthesis, Electrochemistry, and Photophysics of Pd(II) Biladiene Complexes Bearing Varied Substituents at the sp3-Hybridized 10-PositionQiuqi Cai, Anthony T Rice, Craig A Pointer, et al.
Dalton Transactions (Cambridge, England : 2003)|January 18, 2012
Crowded bis ligand complexes of Ttz(Ph,Me) with first row transition metals rearrange due to ligand field effects: structural and electronic characterization (Ttz(Ph,Me) = tris(3-phenyl-5-methyl-1,2,4-triazolyl)borate)Shannon N Oseback, Sarah W Shim, Mukesh Kumar, et al.
Angewandte Chemie (International Ed. in English)|September 30, 2024
Increasing the Donor Strength of Alkenylphosphines by Twisting the C=C Double BondCheng-Han Yu, Yu-Wen Hsiao, Julian Löffler, et al.
ESMO Open|August 30, 2024
PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumorsT A Yap, A D Choudhury, E Hamilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska, Heather M Shaw, Gretchen N Batzel, et al.
Pageof 59